Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial

George R Thompson, Alex Soriano, Athanasios Skoutelis, Jose A Vazquez, Patrick M Honore, Juan P Horcajada, Herbert Spapen, Matteo Bassetti, Luis Ostrosky-Zeichner, Anita F Das, Rolando M Viani, Taylor Sandison, Peter G Pappas, George R Thompson, Alex Soriano, Athanasios Skoutelis, Jose A Vazquez, Patrick M Honore, Juan P Horcajada, Herbert Spapen, Matteo Bassetti, Luis Ostrosky-Zeichner, Anita F Das, Rolando M Viani, Taylor Sandison, Peter G Pappas

Abstract

Background: Rezafungin (RZF) is a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics. STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS) once daily for treatment of candidemia and/or invasive candidiasis (IC).

Methods: Adults with systemic signs and mycological confirmation of candidemia and/or IC were randomized to RZF 400 mg QWk (400 mg), RZF 400 mg on week 1 then 200 mg QWk (400/200 mg), or CAS 70 mg as a loading dose followed by 50 mg daily for ≤4 weeks. Efficacy assessments included overall cure (resolution of signs of candidemia/IC + mycological eradication) at day 14 (primary endpoint), investigator-assessed clinical response at day 14, and 30-day all-cause mortality (ACM) (secondary endpoints), and time to negative blood culture. Safety was evaluated by adverse events and ACM through follow-up.

Results: Of 207 patients enrolled, 183 were in the microbiological intent-to-treat population (~21% IC). Overall cure rates were 60.5% (46/76) for RZF 400 mg, 76.1% (35/46) for RZF 400/200 mg, and 67.2% (41/61) for CAS; investigator-assessed clinical cure rates were 69.7% (53/76), 80.4% (37/46), and 70.5% (43/61), respectively. In total, 30-day ACM was 15.8% for RZF 400 mg, 4.4% for RZF 400/200 mg, and 13.1% for CAS. Candidemia was cleared in 19.5 and 22.8 hours in RZF and CAS patients, respectively. No concerning safety trends were observed; ACM through follow-up was 15.2% (21/138) for RZF and 18.8% (13/69) for CAS.

Conclusions: RZF was safe and efficacious in the treatment of candidemia and/or IC.

Clinical trials registration: NCT02734862.

Keywords: candidemia; echinocandins; rezafungin; systemic antifungal therapy.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Patient flow. ITT population included all consented and randomized patients. Safety population included all patients who received any amount of study drug. The mITT population included all patients in the safety population with documented Candida infection. *Two patients who were randomized to Group 2 received caspofungin and were included in safety analyses of Group 3. Abbreviations: ITT, intent-to-treat; MITT, microbiological intent-to-treat; OD, once daily; QWk, once weekly.
Figure 2.
Figure 2.
Time to negative blood culture following treatment with RZF versus caspofungin (P = .02; log-rank test, post hoc analysis). Abbreviations: IV, intravenous; RZF, rezafungin.

References

    1. Pappas PG, Kauffman CA, Andes DR, et al. . Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1–50.
    1. Andes DR, Safdar N, Baddley JW, et al. ; Mycoses Study Group . Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110–22.
    1. Kullberg BJ, Viscoli C, Pappas PG, et al. . Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial. Clin Infect Dis 2019; 68:1981–9.
    1. Cornely OA, Bassetti M, Calandra T, et al. ; ESCMID Fungal Infection Study Group . ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18(Suppl 7):19–37.
    1. Zhao Y, Prideaux B, Nagasaki Y, et al. . Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model. Antimicrob Agents Chemother 2017; 61. doi: 10.1128/AAC.01009-17.
    1. Grau S, Luque S, Campillo N, et al. . Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother 2015; 70:2854–61.
    1. Howard SJ, Livermore J, Sharp A, et al. . Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother 2011; 55:4880–7.
    1. Bader JC, Bhavnani SM, Andes DR, Ambrose PG. We can do better: a fresh look at echinocandin dosing. J Antimicrob Chemother 2018; 73(suppl_1):i44–50.
    1. Lakota EA, Bader JC, Ong V, et al. . Pharmacological basis of CD101 efficacy: exposure shape matters. Antimicrob Agents Chemother 2017; 61.
    1. Shields RK, Nguyen MH, Press EG, Clancy CJ. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother 2014; 12:7601–5.
    1. Sandison T, Ong V, Lee J, Thye D. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother 2017; 61.
    1. Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR. Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design. Antimicrob Agents Chemother 2018; 11:e01572–18.
    1. Hager CL, Larkin EL, Long LA, Ghannoum MA. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother 2018; 8:2085–8.
    1. Lepak AJ, Zhao M, Andes DR. Determination of pharmacodynamic target exposures for rezafungin against Candida tropicalis and Candida dubliniensis in the neutropenic mouse disseminated candidiasis model. Antimicrob Agents Chemother 2019; 63.
    1. Miesel L, Lin KY, Ong V. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK/PD pharmacometrics of rezafungin efficacy. Pharmacol Res Perspect 2019; 6:e00546.
    1. Flanagan S, Goodman DB, Jandourek A, O’Reilly T, Sandison T. Lack of effect of rezafungin on QT/QTc interval in healthy subjects. Clin Pharmacol Drug Dev 2020; 9:456–65.
    1. Pappas PG, Rotstein CM, Betts RF, et al. . Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883–93.
    1. Wiederhold NP. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med Mycol 2009; 47(Suppl 1):S369–75.
    1. Gangneux JP, Lortholary O, Cornely OA, Pagano L. 9th trends in medical mycology held on 11–14 October 2019, Nice, France, organized under the auspices of EORTC-IDG and ECMM. J Fungi (Basel) 2019; 5.
    1. Safdar A, Rodriguez G, Rolston KV, et al. . High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 3:157–64.
    1. Safdar A, Rodriguez G, Zuniga J, Al Akhrass F, Pande A. High-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events. J Pharm Pract 2015; 28:175–82.
    1. Betts RF, Nucci M, Talwar D, et al. . A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48:1676–84.
    1. Yamazaki S, Nakamura F, Yoshimi A, Ichikawa M, Nannya Y, Kurokawa M. Safety of high-dose micafungin for patients with hematological diseases. Leuk Lymphoma 2014; 55:2572–6.
    1. Reboli AC, Rotstein C, Pappas PG, et al. ; Anidulafungin Study Group . Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472–82.
    1. Jullien V, Azoulay E, Schwebel C, et al. ; EMPIRICUS Trial Study Group . Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. J Antimicrob Chemother 2017; 72:181–9.
    1. Petraitiene R, Petraitis V, Hope WW, Walsh TJ. Intermittent dosing of micafungin is effective for treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Clin Infect Dis 2015; 61(Suppl 6):S643–51.
    1. Zhao Y, Perez WB, Jimenez-Ortigosa C, et al. . CD101: a novel long-acting echinocandin. Cell Microbiol 2016; 18:1308–16.
    1. Maseda E, Grau S, Luque S, et al. . Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. Crit Care 2018; 22:94.
    1. Wasmann RE, Ter Heine R, van Dongen EP, et al. . Pharmacokinetics of anidulafungin in obese and normal-weight adults. Antimicrob Agents Chemother 2018; 62. doi: 10.1128/AAC.00063-18.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel